Ginkgo Bioworks
Synthetic biology platform engineering organisms for pharmaceuticals and materials Visit website
CONVICTION SCORE
WHY THIS SCORE
Methodology- Wins in the Feed: not measured: no sourced item about this company in the Feed in 90 days
- Orbital launches: not applicable: not an orbital launch provider that has flown
- Revenue growth: 0, -59% a year, latest quarter (lower than the year)
- Ladder 0: not a named contributor to any rung on the Dew Point ladder
- Own timelines 15: execution velocity At Risk, editorial and ledgered
- Feed: nothing sourced in 90 days (neutral)
- Form 4: 0 open-market purchases, 6 sales outside a 10b5-1 plan, in 90 days (-18)
- Breadth 50: 1 sector
- Scarcity 75: Biotech & Life Support has 4 covered names
No editorial adjustment. A reviewer may move a computed score by up to 10 points with a reason, recorded on the scorecard.
Inputs frozen Oct 23, 2026 from the site's own feeds: the Feed and Form 4 over 90 days, launches over 365 days, revenue over the trailing year. Next review by Jan 21, 2027. The share price and analyst ratings are not inputs.
DETAILS
SECTORS
PEERS
Biotech & Life SupportScore, then day change (live quotes). Nearest by sector, then by score.
HISTORY
ScorecardRescored on Oct 23, 2026 from the site's own feeds. Strongest: how much of the space economy it covers (60). Weakest: what it has done (0, from revenue growth alone). Methodology ↗
Set from the live market cap of $0.5B on 2026-09-02; the February seed had drifted. Finnhub via fundamentals.json ↗
The Morning Dew, in your inbox
The daily brief, live quotes and the newest signals, every morning. Plus a Friday recap of the week. Nothing else, ever.